The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Open accessAbstract
BACKGROUND: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. METHODS: Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). RESULTS: The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 nonhematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). CONCLUSIONS: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00114101.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lenalidomide is the standard of care for maintenance therapy for most patients.142–147”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [143]
Experimental — accuracy not yet measuredIn the citing paper
“Patients who have disease progression while not on treatment with lenalidomide can often be re-treated effectively with this agent37,38, sometimes multiple times, and typically in combination with proteasome inhibitors such as carfilzomib39 and ixazomib40 or with daratumumab41.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,269
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P., Kalbfleisch, J. D., & Prentice, R. L. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,248
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- 10.1001/archinte.135.1.147 · DOI
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Secondary neoplasms following treatment for multiple myeloma
Germans, S. K., Zhang, B., & Weinberg, O. K. (2025) · Seminars in Diagnostic Pathology · doi:10.1016/j.semdp.2025.150976 · Cited by 1
NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma
Hu, B., Edwards, J. T., Modi, H., Gamez, J., Echeagaray, O. E., Hess, K. N., Ren, Y., Anderson, D., Larráyoz, M., Zhu, J., et al. (2026) · Blood · doi:10.1182/blood.2025031998 · Cited by 1
Slade, M., Fiala, M. A., Kirchmeyer, M., King, J., Gao, F., Schroeder, M. A., Stewart, A. K., Stockerl-Goldstein, K. E., Chen, C. I., & Vij, R. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.09.014 · Cited by 1
Self-citationThe role of maintenance therapy and its cessation in patients with multiple myeloma
Sneider, A. P., & Derman, B. A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2551785 · Cited by 1
Mel, S. D., Tso, A. C. Y., Soekojo, C. Y., Ooi, M. G. M., Lim, C. C., Teo, C., Chen, Y. X., Tan, M. S. Y., Manjeri, A., Lee, Z. Y., et al. (2025) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202532 · Cited by 1
Newly Diagnosed High‐Risk Multiple Myeloma: Outcomes and Management
Yasar, F. Z., & Gorshein, E. (2025) · Advances in Hematology · doi:10.1155/ah/6622365 · Cited by 1
First-line Therapy in Newly Diagnosed Multiple Myeloma
Miller, K. C., & Usmani, S. Z. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-25-0384 · Cited by 1
Nørgaard, J. N., Moore, K. L. F., Slørdahl, T. S., Vik, A., Tvedt, T. H. A., Monsen, H. B., & Schjesvold, F. H. (2026) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.25.0498 · Cited by 1
Multiple myeloma – current status and future directions
Rasche, L., & Knop, S. T. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.841577 · Cited by 1
Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Agents
Shimazaki, C. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.12.004 · Cited by 1
Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients
Fillitz, M., Seebacher, A., & Panny, M. (2015) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-015-0206-8 · Cited by 1
Straka, C., Salwender, H. J., Schnabel, B., Sandherr, M., Wandt, H., Hübel, K., Scheid, C., Metzner, B., Hentrich, M., Franke, D., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.919631 · Cited by 1
Risk of Secondary Primary Malignancies in Maintenance Therapy for Multiple Myeloma
Schecter, J. M., & Lentzsch, S. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.38 · Cited by 1
Autologous Stem Cell Transplantation In Multiple Myeloma: Is It Still The Right Choice?
Tosi, P. (2014) · EMJ Hematology · doi:10.33590/emjhematol/10311182 · Cited by 1
Autologous stem cell transplantation for multiple myeloma: history and future
Shimazaki, C. (2013) · Cited by 1
Yamamoto, M., Ohashi, K., Kakihana, K., Nakamura, Y., Komeno, T., Kojima, H., Morita, S., & Sakamaki, H. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.833 · Cited by 1
Chen, E. C. S. Y. (2014) · Journal of Blood & Lymph · doi:10.4172/2165-7831.1000131 · Cited by 1
Malenda, A., Kołkowska‐Leśniak, A., Szumera‐Ciećkiewicz, A., Lech‐Marańda, E., & Warzocha, K. (2016) · Hematologia · doi:10.5603/hem.2016.0006 · Cited by 1
Richter, J. R., Biran, N., Vesole, D. H., & Siegel, D. S. D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.10.007 · Cited by 1
Treatment of t(4;14) and del(17p) in Multiple Myeloma
Sonneveld, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-61872-2_4 · Cited by 1
Justiz-Vaillant, A. A. (2018) · International biological and biomedical journal · Cited by 1
Overview and Choice of Donor of Hematopoietic Stem Cell Transplantation
Heslop, H. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00103-7 · Cited by 1
Bleeding and Thrombotic Complications
Chaturvedi, S., George, B., & Savani, B. N. (2018) · Springer eBooks · doi:10.1007/978-3-030-02278-5_40 · Cited by 1
How I Manage Frontline Transplant-Eligible Multiple Myeloma in Italy
Montefusco, V., Martinelli, G., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.8954 · Cited by 1
Daratumumab for post-ASCT maintenance treatment of myeloma
Kapoor, P., & Kumar, S. K. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00490-3 · Cited by 1
To transplant or not to transplant in multiple myeloma
LeBlanc, R. (2022) · Canadian Hematology Today · doi:10.58931/cht.2022.119 · Cited by 1
An update on the safety of ixazomib for the treatment of multiple myeloma
Goel, U., & Kumar, S. K. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2130892 · Cited by 2
Rath, C. G., Yoo, C., Cheplowitz, H., Lo, M., Young, R., Guglielmo, J., Saunders, I. M., Banerjee, R. K., Young, R. B., Kumar, A. D., et al. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552221150935 · Cited by 1
Nielsen, L. K., Schjesvold, F. H., Möller, S., Guldbrandsen, N., Hansson, M., Remes, K., Pečeliūnas, V., Abildgaard, N., Gregersen, H., & King, M. T. (2024) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-024-00691-2 · Cited by 1
Bleeding and Thrombotic Complications
Shah, R., Savani, B. N., & Chaturvedi, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-44080-9_40 · Cited by 1
Prevention and Treatment of Relapse by Drugs
Kröger, N. M., & Gagelmann, N. (2024) · Springer eBooks · doi:10.1007/978-3-031-44080-9_58 · Cited by 1
Buck, C., Castillo, F. B., Bettio, E., Land, J., McCourt, O., Poole, H. M., Tarling, R., Yong, K., Popat, R., Lee, L. S. H., et al. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08663-4 · Cited by 1
Bergantim, R., Geraldes, C., Joao, C. M., Lúcio, P., Neves, M. L., Trigo, F., Pedrosa, H., Ventura, M., Santos, S. A., & Ramos, D. (2024) · eJHaem · doi:10.1002/jha2.1035 · Cited by 1
Li, Z., Zhang, W., Huang, F., & Hao, S. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100575 · Cited by 1
Consolidation and Maintenance in De Novo First-Line Multiple Myeloma with Modern Agents
Stoppa, A. M., Coso, D., Fouquet, G., & Leleu, X. P. (2015) · International Journal of Hematologic Oncology · doi:10.2217/ijh.15.3 · Cited by 1
Rabin, N. K., Lai, M., Pratt, G., Morgan, G. J., Snowden, J. A., Bird, J. M., Cook, G., Bowcock, S. J., Owen, R. G., Yong, K., et al. (2014) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12205 · Cited by 1
Ueda, T., Iino, R., Yokoyama, K., Okamoto, S., Asakura, K., Tsukada, Y., Ishizawa, J., Matsuki, E., Ikeda, Y., & Hattori, Y. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1166-y · Cited by 1
Lenalidomide Maintenance Therapy in Patients with Multiple Myeloma
Roziaková, Ĺ., & Mistrík, M. (2013) · Klinicka onkologie · doi:10.14735/amko2013186 · Cited by 1
Autologous stem cell transplantation for multiple myeloma
Nakamura, M., & Sunami, K. (2014) · Journal of Hematopoietic Cell Transplantation · doi:10.7889/hct.3.64 · Cited by 1
Richardson, P. G. G., Palumbo, A. P., Schey, S., Dimopoulos, M. A., Facon, T. T. F., Weisel, K. C., O’Gorman, P., Leleu, X. P., Lacy, M. Q., Streetly, M. J., et al. (2015) · European Oncology & Haematology · doi:10.17925/eoh.2015.11.02.109 · Cited by 1
Self-citationMultiple Myeloma and Other Plasma Cell Neoplasms
Mahindra, A. K., & Ng, A. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00078-2 · Cited by 1
Treatment of Transplant Eligible Patients with Multiple Myeloma
Sonneveld, P., Einsele, H., Brioli, A., & Cavo, M. (2017) · Hematologic malignancies · doi:10.1007/978-3-319-25586-6_3 · Cited by 1
Prevention and Treatment of Relapse by Drugs
Kröger, N. M. (2018) · Springer eBooks · doi:10.1007/978-3-030-02278-5_58 · Cited by 1
Multiple Myeloma: Front Line Therapy and Autologous Stem Cell Transplantation
Kumar, L. (2020) · Annals of the National Academy of Medical Sciences (India) · doi:10.1055/s-0040-1712792 · Cited by 1
Steensma, D. P., & Stone, R. M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00099-0 · Cited by 1
Huang, L., Kuang, Y., Jiang, Z., Zhu, Y., Luo, X., Shi, F., Hu, S., & Gao, X. (2020) · Open Medicine · doi:10.1515/med-2020-0136 · Cited by 1
Romano, A., Santoro, M., Conticello, C., Siragusa, S. M., Raimondo, F. D., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04141-5 · Cited by 1
Maintenance regimens after a second autologous transplant for multiple myeloma
Mohyuddin, G. R., Okoniewski, M., Diab, O. A., Ganguly, S., Shune, L. O., Abdallah, A.-O. A., McGuirk, J. P., & McClune, B. L. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1842402 · Cited by 1
Self-citationThe evolving role and utility of off-label drug use in multiple myeloma
Stoeckle, J. H., Davies, F. E., Williams, L. S., Boyle, E. M., & Morgan, G. J. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00050 · Cited by 1
Multiple Myeloma: Risk Stratification and Toxicity Management
Richards, T., & Lee, H. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.3.10 · Cited by 1
Krishnan, A. Y., Nathwani, N., Amanam, I. U., & Gupta, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_5 · Cited by 1
Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma
Puliafito, B. R., Oveisi, D. R., Fanous, C., & El‐Masry, M. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-249637 · Cited by 1
Issues of front-line therapy for multiple myeloma – the standard of care
Rosiñol, L., & Bladé, J. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.896460 · Cited by 1
Transplantation for Myeloma: Work in Progress
Palumbo, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1437 · Cited by 1
Future needs and wants in medical education--the UPM experience.
Azhar, M. Z. (2005) · PubMed · Cited by 1
Galy, A. S. D., Michonneau, D., & Socié, G. (2021) · Wiley eBooks · doi:10.1002/9781119612780.ch12 · Cited by 1
Lenalidomide maintenance based on a genetic profile
Mateos, M., & González‐Calle, V. (2023) · Blood · doi:10.1182/blood.2022019352 · Cited by 1
Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma
Mian, H. S., & Costa, L. J. (2026) · New England Journal of Medicine · doi:10.1056/nejme2604761 · Cited by 1
Schuster, S. R., & Mikhael, J. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_23
Zielgerichtete Therapien bei hämatologischen Erkrankungen
Hochhaus, A., Rosée, P. G. L., Mügge, L., Sayer, H. G., & Scholl, S. (2013) · Der Onkologe · doi:10.1007/s00761-013-2497-x
Konsolidierungs- und Erhaltungstherapie beim multiplen Myelom
Zojer, N., & Ludwig, H. (2014) · Der Onkologe · doi:10.1007/s00761-013-2572-3
Cell cycle regulation and myeloma precursor cells
Quinn, J., & Yong, K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511862465.004
Treatment of transplant-eligible patients
Mohty, M., Malard, F., & Harousseau, J. (2015) · Springer eBooks · doi:10.1007/978-3-319-18218-6_3
Multiple Myelomada Otolog Periferik Kök Hücre Nakli Sonrası Lenalidomid Deneyimlerimiz
Andıç, N., Özkocaman, V., Ateşoğlu, E. B., Özkalemkaş, F., Gedük, A., & Akay, O. M. (2015) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.35901
Autologous Stem Cell Transplantation in the Management of Multiple Myeloma
Gertz, M. A., & Reeder, C. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8520-9_10
The Devil is in the Details: Confidentiality Challenges in the Age of Genetics
Daly, B. J., Rosko, A. E., Zhang, S., & Lazarus, H. M. (2014) · HEC Forum · doi:10.1007/s10730-014-9245-5
Impediments to Curing Myeloma in 2012
Chauhan, N., Barlogie, B., & Usmani, S. Z. (2012) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.11
Clinical Pathologic Conference Case 2: A Diffuse Swelling of the Neck
Ferreira, L., Efebera, Y. A., & Allen, C. M. (2013) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2013.01.045
Stellenwert der autologen Stammzelltransplantation und der Lenalidomid-Erhaltung
Rasche, L., & Einsele, H. (2015) · Info Onkologie · doi:10.1007/s15004-015-0760-6
What Can We Attribute Secondary Malignancy to: Drugs or the Innate System?
Johnson, S., Barlogie, B., & Usmani, S. Z. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.34
Lenalidomide maintenance in myeloma
Rajkumar, S. V. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.100-c2
The evolving field of post-transplant therapy in multiple myeloma
Holstein, S. A., & McCarthy, P. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.72
Self-citationManifestaciones otorrinolaringológicas de las hemopatías del adulto
Lisan, Q., Boussen, I., Page, P. L., Pons, Y., de Régloix, S. B., Raynal, M., & Kossowski, M. (2015) · EMC - Otorrinolaringología · doi:10.1016/s1632-3475(15)69985-4
Post-transplant therapy in multiple myeloma: a hung jury?
Kumar, S. K. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)00024-6
POMALIDOMID – nowy immunomodulujący lek w terapii szpiczaka plazmocytowego
Jurczyszyn, A. J., Usnarska‐Zubkiewicz, L., Engel, A., Butrym, A. K., Mazur, G. J., & Skotnicki, A. B. (2014) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2014.04.003
Manifestazioni otorinolaringoiatriche delle emopatie dell’adulto
Lisan, Q., Boussen, I., Page, P. L., Pons, Y., de Régloix, S. B., Raynal, M., & Kossowski, M. (2015) · EMC - Otorinolaringoiatria · doi:10.1016/s1639-870x(15)70597-0
Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma
Lonial, S. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.6
Leczenie podtrzymujące w szpiczaku plazmocytowym
Grosicki, S. (2013) · Acta Haematologica Polonica · doi:10.1016/j.achaem.2013.02.012
Giebel, S., & Saduś‐Wojciechowska, M. (2012) · Acta Haematologica Polonica · doi:10.1016/s0001-5814(12)34002-4
Evans, H. L. (2014) · Journal of Leukemia · doi:10.4172/2329-6917.1000141
A Case of Secondary Primary Malignancy after Lenalidomide Therapy for Multiple Myeloma
Lee, H. J., Kim, E. S., Lee, H. J., Kang, S. H., Park, I., Lee, J. H., & Kim, S. (2014) · Korean Journal of Medicine · doi:10.3904/kjm.2014.86.3.353
High-Risk Myeloma: When To Transplant—Or Not
Eicher, D. M., Lonial, S., Cavallo, F., Palumbo, A. P., Nair, B. P., Waheed, S., Hofmeister, C. C., & Rogers, H. J. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.016
Self-citationDeriving New Treatment Strategies in Multiple Myeloma
Podar, K. (2012) · International Journal of Hematologic Oncology · doi:10.2217/ijh.12.10
Multiple myeloma: optimal management and long-term disease control
Sriskandarajah, P., & Davies, F. E. (2014) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s46576
Devine, S. M. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.11.035
Self-citationFront-line lenalidomide therapy in patients with newly diagnosed multiple myeloma
Cejalvo, M. J., & de la Rubia, J. (2015) · Future Oncology · doi:10.2217/fon.15.51
Autologe Stammzelltransplantation bei Myelompatienten
Zojer, N. (2015) · Wiener klinisches Magazin · doi:10.1007/s00740-015-0077-y
Continuous therapy with lenalidomide in multiple myeloma
Bahlis, N. J. (2013)
Continued role for ASCT in multiple myeloma
McCarthy, P. L., & Holstein, S. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00457-x
Self-citationTakano, J., Hagiwara, S., & Miwa, A. (2015) · Rare Tumors · doi:10.4081/rt.2015.5949
Biran, N., & Vesole, D. H. (2015) · American Journal of Hematology / Oncology®
Ex Vivo Expanded Cord Blood Natural Killer Cells as a Novel Therapeutic for Multiple Myeloma
Shah, N. D. (2015) · Digital Commons-TMC (Texas Medical Center)
Postępy w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego
Jamroziak, K. (2015) · Hematologia · doi:10.5603/hem.2015.0011
Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma
Eser, A., Tanrıkulu, F. P., & Tuğlular, A. T. (2016) · Medical Science and Discovery · doi:10.17546/msd.84603
Continued role for ASCT in multiple myeloma
Bolla, M. (2015)
Allogeneic transplantation for multiple myeloma: yes, no or maybe?
Bruno, B. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.12
Mai, E. K., & Goldschmidt, H. (2014) · best practice onkologie · doi:10.1007/s11654-014-0512-3
Szpiczak plazmocytowy — praktyczne aspekty dotyczące diagnostyki i leczenia
Charliński, G., & Wiater, E. (2014)
Metadata
- Authors
- McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R. T., Gabriel, D. A., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Anderson, K. C., & Linker, C.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Duke University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Abramson Cancer Center (US)
- University of Minnesota Medical Center (US)
- Washington University in St. Louis (US)
- University of Florida (US)
- University of Wisconsin–Madison (US)
- State University of New York (US)
- Mount Sinai Hospital (US)
- Oregon Health & Science University (US)
- University of North Carolina at Chapel Hill (US)
- BMT Group (United States) (US)
- University of California, San Francisco (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of Chicago Medical Center (US)
- Medical College of Wisconsin (US)
- ORCID
- McCarthy, Philip L.
- Owzar, Kouros
- Hofmeister, Craig C.
- Hassoun, Hani
- Richardson, Paul G.
- Giralt, Sergio
- Stadtmauer, Edward A.
- Weisdorf, Daniel J.
- Vij, Ravi
- Moreb, Jan S.
- Callander, Natalie Scott
- Gentile, Teresa
- Isola, Luis
- Maziarz, Richard T.
- Landau, Heather
- Martin, Thomas
- Qazilbash, Muzaffar H.
- McClune, Brian
- Jiang, Chen
- Bennett, Elizabeth
- Kelly, Michael
- Rosenbaum, Cara
- Hari, Parameswaran
- Pasquini, Marcelo C.
- Horowitz, Mary M.
- Devine, Steven M.
- Anderson, Kenneth C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-05-10
- Volume
- 366
- Issue
- 19
- Pages
- 1770-1781
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3744390
- OpenAlex
- W2125721471
- Semantic Scholar
- b20a8f57aae32a45c1804976b107b4ba1609688f
- Cited by
- 1,147
- References
- 42
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 40 · 2023: 40 · 2022: 51 · 2021: 74 · 2020: 81 · 2019: 70 · 2018: 82 · 2017: 104 · 2016: 107 · 2015: 100 · 2014: 113 · 2013: 144 · 2012: 81
- FWCI
- 93.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U10HL069334, U10HL069301, U10HL069348, U10HL109526, U01HL069294, U10HL069294, U10HL069330, U10HL069315, U10HL069290, U10HL069286, UG1HL069286, UG1HL069315)
- National Cancer Institute (U10CA033601, P50CA100707, U10CA031946, U10CA021115, U24CA076518)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, multiple myeloma, autologous stem cell transplantation, maintenance therapy, time to progression, overall survival, secondary malignancies, hematologic adverse events, drug toxicity
- MeSH terms
- Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
